



Geisinger Health Plan Policies and Procedure Manual

Policy: MP249

Section: Medical Benefit Policy

Subject: Bioimpedance Spectroscopy

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Bioimpedance Spectroscopy

II. Purpose/Objective:

To provide a policy of coverage regarding Bioimpedance Spectroscopy

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION:

Bioelectrical impedance analysis (BIA) is a noninvasive technique which passes a small electrical current through the body, then measures the amount of resistance to the flow of the current. The BIA measurement is thought to be inversely proportional to the volume of fluid in tissue, thus it can be used to estimate the volume of water in a person's body. Researchers have investigated BIA as a tool for the early detection of lymphedema.

EXCLUSIONS:

The Plan does **NOT** provide coverage for the use of bioimpedance spectroscopy (e.g., ImpediMed L-Dex U400; MoistureMeterD, etc.) for the assessment of lymphedema because it is **considered experimental, investigational or unproven**. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this test on health outcomes when compared to established tests or technologies.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH:

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

- 0358T Bioelectrical impedance analysis whole body composition assessment, supine position, with interpretation and Report
- 0546T Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report
- 93702 Bioimpedance spectroscopy (bis), extracellular fluid analysis for lymphedema assessment(s)
- 93799 Unlisted cardiovascular service or procedure

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Bar Ad V, Cheville A, Solin LJ, et al. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. *Int J Radiat Oncol Biol Phys.* 2010; 76(1):85-90.

Czerniec SA, Ward LC, Refshauge KM, et al. Assessment of breast cancer-related arm lymphedema--comparison of physical measurement methods and self-report. *Cancer Invest.* 2010; 28(1):54-62.

Hayes S, Janda M, Cornish B, et al. Lymphedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence, and identifiable risk factors. *Lymphology.* 2008; 41(1):18-28.

Ridner SH, Dietrich MS, Deng J, et al. Bioelectrical impedance for detecting upper limb lymphedema in nonlaboratory settings. *Lymphat Res Biol.* 2009; 7(1):11-15.

Stout Gergich NL, Pfalzer LA, McGarvey C, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. *Cancer.* 2008; 112(12):2809-2819.

Agency for Healthcare Research and Quality. Diagnosis and treatment of secondary lymphedema. Technology Assessment Report. 2010 May. Project ID LYMT0908. Available at: <http://www.ahrq.gov/clinic/techix.htm>. Accessed November 2010.

U.S. Food and Drug Administration 510(k) Premarket Notification Database. ImpediMed L-Dex U400 BIS Extra Cellular Fluid Analysis. No. K080825. Rockville, MD: FDA. October 3, 2008. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf8/K080825.pdf. Accessed November 2010

Oremus M, Walker K, Dayes I, Raina P. Diagnosis and treatment of secondary lymphedema. Technology Assessment Project ID:LYMT0908; May 28, 2010. Available at: <http://www.cmms.hhs.gov/determinationprocess/downloads/id66aTA.pdf>. Accessed January 6 2012

Geisinger Technology Assessment Committee Triage Group. Bioimpedance Spectroscopy for the Assessment, Diagnosis, or Management of Individuals with Known or Suspected Lymphedema. April 2013.

Czerniec SA, Ward LC, Lee MJ, et al. Segmental measurement of breast cancer-related arm lymphedema using perometry and bioimpedance spectroscopy. Support Care Cancer. 2011; 19(5):703-710.

Ward LC, Czerniec S, Kilbreath SL. Quantitative bioimpedance spectroscopy for the assessment of lymphedema. Breast Cancer Res Treat. 2009 Oct;117(3):541-7.

Ward L, Winall A, Isenring E, et al. Assessment of bilateral limb lymphedema by bioelectrical impedance spectroscopy. Int J Gynecol Cancer. 2011 Feb;21(2):409-18.

Warren AG, Janz BA, Slavin SA et al. The use of bioimpedance analysis to evaluate lymphedema. Ann Plast Surg 2007; 58(5):541-3.

Smoot BJ, Wong JF, Dodd MJ. Comparison of diagnostic accuracy of clinical measures of breast cancer-related lymphedema: area under the curve. Arch Phys Med Rehabil 2011; 92(4):603-10.

Vicini F, Shah C, Lyden M et al. Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. Clin Breast Cancer 2012; 12(2):133-7.

Jain MS, Danoff JV, Paul SM. Correlation between bioelectrical spectroscopy and perometry in assessment of upper extremity swelling. Lymphology. Jun 2010;43(2):85-94.

Ward LC, Czerneic S, Kilbreath SL. Operational equivalence of bioimpedance indices and perometry for the assessment of unilateral arm lymphedema. Lymphat Res Biol 2009;7(2):81-85.

Moseley A, Piller N. Reliability of bioimpedance spectroscopy and tonometry after breast conserving cancer treatment. Lymphat Res Biol.2008;6(2):85-87

Gaw R, Box R, Cornish B, Bioimpedance in the assessment of unilateral lymphedema of a limb: the optimal frequency. Lymphat Res Biol. 2011;92):93-99

Berlit, S, Brade, J, Tuschy, B, Hornemann, A, Leweling, H, Eghardt, V, and Sutterlin, M. Comparing bioelectrical impedance values in assessing early upper limb lymphedema after breast cancer surgery. In Vivo. 2012;26(5):863-867

Dylke ES, Alsobayel H, Ward LC, et al. Use of impedance ratios to assess hand swelling in lymphedema. Phlebology 2012 Nov 27 (e-pub ahead of print)

Barrio AV, Eaton A, Frazier TG. A prospective validation study of bioimpedance with volume displacement in early-stage breast cancer patients at risk for lymphedema. Ann Surg Oncol. Dec 2015;22 Suppl 3:370-375.

Erdogan Iyigun, Z, Selamoglu, D, Alco, G, et al. Bioelectrical impedance for detecting and monitoring lymphedema in patients with breast cancer. Preliminary results of the florence nightingale breast study group. Lymphatic research and biology. 2015 Mar;13(1):40-5.

Laidley A, Anglin B. The impact of L-Dex((R)) Measurements in assessing breast cancer-related lymphedema as part of routine clinical practice. Front Oncol. 2016;6:192.

Dylke, ES, Schembri, GP, Bailey, DL, et al. Diagnosis of upper limb lymphedema: development of an evidence-based approach. *Acta oncologica* 2016 Dec;55(12):1477-83.

Kaufmann DI, Shah C, Vinci F, et al. Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema. *Breast Cancer Res Treat.* 2017; 166(3): 809–815.

Whitworth PW, Shah C, Vinci F, Cooper A. Preventing Breast Cancer-Related Lymphedema in High-Risk Patients: The Impact of a Structured Surveillance Protocol Using Bioimpedance Spectroscopy. *Front Oncol.* 2018 Jun 12;8:197

Kilgore LJ, Korentager SS, et al Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions. *Ann Surg Oncol.* 2018 Oct;25(10):2948-2952.

Vicini F, Shah C, Whitworth P, et al. Correlation of Bioimpedance Spectroscopy with Risk Factors for the Development of Breast Cancer-Related Lymphedema. *Lymphat Res Biol.* 2018 Aug 22

Ridner SH, Dietrich MS, Cowher MS, et. al. A randomized trial evaluating bioimpedance spectroscopy versus tape measurement for the prevention of lymphedema following treatment for breast cancer: interim analysis. *Ann Surg Oncol* 2019 Oct;26(10):3250-3259

Lim SM, Han Y, Kim S, et.al. Utilization of bioelectrical impedance analysis for detection of lymphedema in breast cancer survivors: a prospective cross-section study. *BMC Cancer* 2019 Jul 8;19(1):669

Cho KH, Han EY, Lee SA, et. al. Feasibility of bioimpedance analysis to assess the outcome of complex decongestive therapy in cancer treatment-related lymphedema. *Front Oncol* 2020;10:111

Geisinger Technology Assessment Committee. Bioimpedance Spectroscopy for the Assessment, Diagnosis, or Management of Individuals with Known or Suspected Lymphedema. Re-evaluated January 2023 (27 References)

This policy will be revised as necessary and reviewed no less than annually.

Devised: 1/11

Revised: 1/20 (add technology examples)

Reviewed: 1/12, 1/13, 1/14, 1/15, 1/16, 1/17, 1/18, 1/19, 1/21, 1/22, 2/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.